Gilteritinib
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Adult Indications and Dosage
Plasma Concentration
- After 15 days, the plasma concentration becomes steady
- Maximum Concentration: 374 ng/mL
- AUC: 6943 ng.h/mL
- The Data is different in people who are fasting
- The Maximum Concentration decreased by 26%
- AUC decreased by 10%
Excretion
- About 64.5% of the administered dose is excreted in the feces
- About 16.4% of the administered dose goes through the urine
Distribution
- Central Volume of Distribution is approximately 1092 L
- Peripheral Volume of Distribution is approximately 1100 L
Pediatric Indications and Dosage
- There is limited information on the indications and dosage of the drug Gilteritinib on children.
Contraidications
- Hypersensitivity under any ingredient in Gilteritinib
Warnings
Adverse Reactions
Differentiation Syndrome
- May result in some "life-threatening symptoms" known as differentiation syndrome
- Contact doctor immediately if any of these symptoms occur:
- Fever, cough rash, rapid weight gain, vertigo, urination problems, joint swelling, difficulty breathing, chest pain, or joint pain
Side Effects
- If persists, call a doctor:
- joint/muscle pain, severe tiredness, acute vomiting and nausea, diarrhea, mouth sores, loss in taste/ appetite, headache or insomnia
- More Serious
- Seizures, difference in heartbeat, persisting pain in the abdomen region that could spread to the back
Drug Interactions
Use in Specific Populations
Administration and Monitoring
IV Compatibility
- There is limited information about Gilteritinib's compatibility with IV transfusions
Overdosage
Pharmacology
- Inhibited the receptor tyrosine kinase which regulates FLT3 in acute myeloid luekemia
Trials
- Phase 1 and 2:
- Complete response: 41%
- Overall Response Rate: 52%
- Duration of Response(Median): 20 weeks
- Overall Survival(Median): 31 weeks
- Phase 3:
- Complete Remission
- Complete Remission with limited blood recovery: 21% of patients
Clinical Studies
How is it Supplied
- The authorized dose for patients on Gilteritinib is 120 mg but may go up to 200 mg is the response from the patient is dissatisfactory
Patient Counseling Information
Precautions with Alcohol
There is limited information on Alcohol-Gilteritinib interactions. Talk to your doctor for further instruction on consuming alcohol with Gilteritinib.
Brand Names
- Xospata
Names of Drugs that Look Alike
- There is limited information on Gilteritinib look-alike drugs
Drug Shortage Status
Price
Contraindicated Medications
{{MedCondContrAbs |MedCond = NameOfTheContraindication|Drug1|Drug2|Drug3}}